The New Rules of Retina Drug Development - Poll - MDSpire

The New Rules of Retina Drug Development

In a panel at the Retina Innovation Summit in Montreal, regulatory experts, drug developers, academic advisors, and investors discussed how evolving FDA guidance is reshaping the path from clinical trials to approval.

  • By

  • Jim Gallagher, senior managing editor

  • July 15, 2026

  • 5 min

Share

Original Source(s)

The New Rules of Retina Drug Development

  • by Jim Gallagher, senior managing editor

  • July 15, 2026

Related Content

Endogenous Endophthalmitis and Missed Diagnoses

Retrospective study describes how endogenous endophthalmitis often presents without systemic symptoms

  • July 21, 2026

  • 3 min
Elevated GDF15 in ocular fluids of patients with proliferative diabetic retinopathy

The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.